Monitoring Early Efficacy of the Checkpoint Immunotherapy Based on Fluorescence Lifetime Imaging Microscopy of the Patient-Derived Lymphocyte Subsets.

Authors

Diana V Yuzhakova, Anastasia I Kononova, Anna V Izosimova, Margarita M Sazhina, Ilya D Shchechkin, Artem M Mozherov, Pavel A Bureev, Dmitry A Kuzmin, Alena I Gavrina, Irina S Shumskaya, Sergey V Gamayunov, Marina V Shirmanova

Published in

Biochemistry. Biokhimiia. Volume 91. Issue 7. Pages 1276-1286.

Abstract

Despite the success of immune checkpoint inhibitor (ICI) therapy, the problem of resistance makes the search for early response biomarkers critical. This study investigates the potential of monitoring autofluorescence of the NAD(P)H coenzyme in the T-lymphocyte subsets to assess early treatment efficacy. The ability of NAD(P)H FLIM to reflect sensitivity to ICI therapy was tested on the B16F0 mouse melanoma model and validated in the pilot study of the samples from melanoma patients during treatment. The mean fluorescence lifetime of NAD(P)H, τ_m, showed the best correlation with subsequent clinical response and was identified as a sensitive marker of early lymphocyte activation following anti-PD-1 or combination therapy. In the patients who responded to treatment, an increase in τ_m was observed, associated with metabolic reprogramming toward enhanced biosynthetic and bioenergetic pathways, as confirmed by the standard molecular analysis. Thus, the proposed approach represents a promising solution for personalized monitoring of early immunotherapy efficacy.

PMID:
42633724
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.